Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

562 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Salivary Duct Carcinoma.
Takahashi H, Tada Y, Saotome T, Akazawa K, Ojiri H, Fushimi C, Masubuchi T, Matsuki T, Tani K, Osamura RY, Hirai H, Yamada S, Kawakita D, Miura K, Kamata SE, Nagao T. Takahashi H, et al. Among authors: akazawa k. J Clin Oncol. 2019 Jan 10;37(2):125-134. doi: 10.1200/JCO.18.00545. Epub 2018 Nov 19. J Clin Oncol. 2019. PMID: 30452336 Clinical Trial.
Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma.
Kawakita D, Nagao T, Takahashi H, Kano S, Honma Y, Hirai H, Saigusa N, Akazawa K, Tani K, Ojiri H, Tsukahara K, Ozawa H, Okami K, Kondo T, Togashi T, Fushimi C, Shimura T, Shimizu A, Okamoto I, Okada T, Imanishi Y, Watanabe Y, Otsuka K, Sakai A, Ebisumoto K, Sato Y, Yamazaki K, Ueki Y, Hanazawa T, Saito Y, Ando M, Matsuki T, Nakaguro M, Sato Y, Urano M, Utsumi Y, Kohsaka S, Saotome T, Tada Y. Kawakita D, et al. Among authors: akazawa k. Ther Adv Med Oncol. 2022 Sep 6;14:17588359221119538. doi: 10.1177/17588359221119538. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 36090801 Free PMC article.
Impact of the Relative Dose Intensity of Neoadjuvant Chemotherapy With Anthracycline Followed by Taxane on the Survival of Patients With Human Epidermal Growth Factor Receptor 2-negative Breast Cancer: The JONIE1 Study.
Yamada A, Nakazawa K, Akazawa K, Narui K, Endo I, Hasegawa Y, Kohno N, Ishikawa T; JONIE STUDY GROUP. Yamada A, et al. Among authors: akazawa k. Anticancer Res. 2021 Feb;41(2):1063-1068. doi: 10.21873/anticanres.14863. Anticancer Res. 2021. PMID: 33517316 Clinical Trial.
Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.
Kudo M, Ueshima K, Yokosuka O, Ogasawara S, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, Hino K, Kumada T, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Kanai F, Akazawa K, Yoshimura KI, Johnson P, Arai Y; SILIUS study group. Kudo M, et al. Among authors: akazawa k. Lancet Gastroenterol Hepatol. 2018 Jun;3(6):424-432. doi: 10.1016/S2468-1253(18)30078-5. Epub 2018 Apr 7. Lancet Gastroenterol Hepatol. 2018. PMID: 29631810 Clinical Trial.
Single-dose intravenous administration of recombinant human erythropoietin is a promising treatment for patients with acute myocardial infarction - randomized controlled pilot trial of EPO/AMI-1 study -.
Ozawa T, Toba K, Suzuki H, Kato K, Iso Y, Akutsu Y, Kobayashi Y, Takeyama Y, Kobayashi N, Yoshimura N, Akazawa K, Aizawa Y; EPO/AMI-I Pilot Study Researchers. Ozawa T, et al. Among authors: akazawa k. Circ J. 2010 Jul;74(7):1415-23. doi: 10.1253/circj.cj-10-0109. Epub 2010 May 22. Circ J. 2010. PMID: 20501957 Free article. Clinical Trial.
Targeting complete response with upfront bortezomib consolidation versus observation after the achievement of complete response following autologous transplantation for multiple myeloma (TUBA study).
Nakasone H, Terasako-Saito K, Hirano T, Wake A, Shimizu S, Kurita N, Yamazaki E, Usuki K, Akazawa K, Kanda J, Minauchi K, Yamamoto G, Tanimoto S, Kamoshita M, Yokoyama Y, Miyaoka E, Ota S, Kako S, Izutsu K, Kanda Y. Nakasone H, et al. Among authors: akazawa k. Hematol Oncol. 2018 Feb;36(1):202-209. doi: 10.1002/hon.2452. Epub 2017 Jul 6. Hematol Oncol. 2018. PMID: 28681529
External validation of the UCSF-CAPRA (University of California, San Francisco, Cancer of the Prostate Risk Assessment) in Japanese patients receiving radical prostatectomy.
Ishizaki F, Hoque MA, Nishiyama T, Kawasaki T, Kasahara T, Hara N, Takizawa I, Saito T, Kitamura Y, Akazawa K, Takahashi K. Ishizaki F, et al. Among authors: akazawa k. Jpn J Clin Oncol. 2011 Nov;41(11):1259-64. doi: 10.1093/jjco/hyr136. Epub 2011 Sep 22. Jpn J Clin Oncol. 2011. PMID: 21940731
Efficacy and Safety of Long-Term Sirolimus Therapy for Asian Patients with Lymphangioleiomyomatosis.
Takada T, Mikami A, Kitamura N, Seyama K, Inoue Y, Nagai K, Suzuki M, Moriyama H, Akasaka K, Tazawa R, Hirai T, Mishima M, Hayashida M, Hirose M, Sugimoto C, Arai T, Hattori N, Watanabe K, Tamada T, Yoshizawa H, Akazawa K, Tanaka T, Yagi K, Young LR, McCormack FX, Nakata K. Takada T, et al. Among authors: akazawa k. Ann Am Thorac Soc. 2016 Nov;13(11):1912-1922. doi: 10.1513/AnnalsATS.201605-335OC. Ann Am Thorac Soc. 2016. PMID: 27513278 Clinical Trial.
Reduced-dose WBRT combined with SRS for 1-4 brain metastases aiming at minimizing neurocognitive function deterioration without compromising brain tumor control.
Nakano T, Aoyama H, Onodera S, Igaki H, Matsumoto Y, Kanemoto A, Shimamoto S, Matsuo M, Tanaka H, Oya N, Matsuyama T, Ohta A, Maruyama K, Tanaka T, Kitamura N, Akazawa K, Maebayashi K; Japanese Radiation Oncology Study Group 13-1 (JROSG13-1) Investigators. Nakano T, et al. Among authors: akazawa k. Clin Transl Radiat Oncol. 2022 Sep 27;37:116-129. doi: 10.1016/j.ctro.2022.09.005. eCollection 2022 Nov. Clin Transl Radiat Oncol. 2022. PMID: 36199814 Free PMC article.
562 results